Atrium re-evaluates business
This article was originally published in The Tan Sheet
Executive Summary
In an effort to better position itself as a leader in the health and nutritional products arena, Atrium Innovations is considering a sale of its active ingredients and specialty chemicals division, the Canadian nutritional products marketer announces Dec. 18. A sale of the division would "strengthen Atrium with a targeted vision and development strategy in the high potential nutritional supplements market," the Quebec-based firm says, noting it plans to act as a consolidator in the fragmented segment. Atrium strengthened its health division with the purchase of German-based Mucos in July and was recently granted permission to sell Mucos' enzyme-based supplement Wobenzym N in the U.S. (1"The Tan Sheet" Nov. 26, 2007, In Brief)...
You may also be interested in...
Atrium divests chemicals division
Health and nutrition product marketer Atrium has completed the sale of its active ingredients and specialty chemicals division to Unipex Group for $166.4 million in cash, "subject to post-closing working capital adjustment," the company announces May 22. Proceeds will provide the firm better financial flexibility to pursue its corporate strategy, the Quebec City, Canada-based company notes. With the sale, Atrium has reached its goal of focusing entirely on health and nutrition products (1"The Tan Sheet" Jan. 6, 2008, In Brief)...
Atrium given exclusive rights
Atrium Innovations will be able to "accelerate its growth and development" in the U.S. following an American court ruling allowing the firm to sell enzyme-based supplement Wobenzym N in the country, the Canadian firm announces Nov. 15. Concurrently, Marlyn Neutraceuticals is ordered to stop using the Wobenzym N trademark and selling products under the brand name. Wobenzym N, a product intended to benefit the health of joints, muscles and tendons, was developed by German company Mucos, which Atrium acquired for $175 million in July 2007. At the time, the firm projected the purchase would accelerate its earnings by approximately $27 million (1"The Tan Sheet," July 23, 2007, In Brief). Annual European sales of Wobenzym N currently are more than $90 million...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.